• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RAMUCIRUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • RAMUCIRUMAB chembl:CHEMBL1743062 ApprovedAntineoplastic

    Alternate Names:

    1121B
    CYRAMZA
    IMC-1121B
    LY3009806
    RAMUCIRUMAB
    chemidplus:947687-13-0
    drugbank:05578
    chembl:CHEMBL1743062
    rxcui:1535922

    Drug Info:

    FDA Approval Colorectal cancer, Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma, Non-small cell lung cancer
    Drug Class Therapeutic Antibodies
    FDA Approval not approved
    Drug Class antibody
    Drug Indications antineoplastic agent
    (5 More Sources)

    Publications:

    Goodkin et al., 1990, Arteriovenous malformation and glioma: coexistent or sequential? Case report., J. Neurosurg.
    Spratlin et al., 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2., J. Clin. Oncol.
    Tabernero et al., 2015, Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study., Lancet Oncol.
    Mackey et al., 2015, Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer., J. Clin. Oncol.
  • RAMUCIRUMAB   KDR

    Interaction Score: 0.65

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name IMC-1121B
    Novel drug target Established target
    Notes

    PMIDs:
    2182794 20048182


    Sources:
    TALC MyCancerGenome TdgClinicalTrial JAX-CKB ChemblInteractions TTD

  • RAMUCIRUMAB   PDGFRA

    Interaction Score: 0.32

    Interaction Types & Directionality:
    antibody (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome

  • RAMUCIRUMAB   KRAS

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ramucirumab + FOLFIRI
    Indication/Tumor Type colorectal cancer
    Response Type sensitive

    PMIDs:
    25877855


    Sources:
    JAX-CKB PharmGKB

  • RAMUCIRUMAB   ALK

    Interaction Score: 0.19

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RAMUCIRUMAB   ERBB2

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase III
    Response Type no benefit

    PMIDs:
    25185099


    Sources:
    JAX-CKB

  • RAMUCIRUMAB   EGFR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB FDA

  • MyCancerGenome: RAMUCIRUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    IMC-3G3 Development Name
    RAMUCIRUMAB Generic Name
    IMC-1121B Development Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Colorectal cancer, Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma, Non-small cell lung cancer

    Publications:

  • TdgClinicalTrial: IMC-1121B

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antineoplastic agent
    Drug Class antibody
    FDA Approval not approved

    Publications:

  • JAX-CKB: Ramucirumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Tabernero et al., 2015, Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study., Lancet Oncol.
    Mackey et al., 2015, Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer., J. Clin. Oncol.
    Spratlin et al., 2010, Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2., J. Clin. Oncol.

  • TALC: RAMUCIRUMAB

    • Version: 12-May-2016

    Alternate Names:
    RAMUCIRUMAB Primary Drug Name
    RAMUCIRUMAB Drug Generic Name
    IMC-1121B Drug Synonym

    Drug Info:

    Publications:

  • TTD: Ramucirumab

    • Version: 2020.06.01

    Alternate Names:
    D09HVD TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1743062

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1743062

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • PharmGKB: ramucirumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Ramucirumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21